![Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/e78fae40-ec72-4336-88b6-6de6833ae326/gr2_lrg.jpg)
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
![Current Oncology | Free Full-Text | Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis Current Oncology | Free Full-Text | Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis](https://www.mdpi.com/curroncol/curroncol-30-00057/article_deploy/html/images/curroncol-30-00057-g005.png)
Current Oncology | Free Full-Text | Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis
![Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer | Business Wire Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer | Business Wire](https://mms.businesswire.com/media/20220314005623/en/611316/23/Exelixis_Logo_JPG.jpg)
Exelixis Announces Final Overall Survival Results from Phase 3 COSMIC-312 Trial of Cabozantinib in Combination with an Immune Checkpoint Inhibitor in Patients with Previously Untreated Advanced Liver Cancer | Business Wire
![COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram](https://www.researchgate.net/publication/351523048/figure/tbl1/AS:1028856655908868@1622309950810/Ongoing-clinical-trials-of-cabozantinib-in-HCC_Q320.jpg)
COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram
Dr Joseph McCollom DO on X: "Combos, combos combos! Dr Lipika Goyal from @MGHCancerCenter discusses combining TKIs and #IO with COSMIC-312, LEAP-002 and early phase Lenva + Pembro 1st line for #HCC #
![COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram](https://www.researchgate.net/publication/351523048/figure/fig4/AS:1028856655908867@1622309950788/COSMIC-312-Study-Design-Reproduced-with-permission-from-Kelley-et-al-91_Q320.jpg)
COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram
![New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma | International Journal of Clinical Oncology New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma | International Journal of Clinical Oncology](https://media.springernature.com/m685/springer-static/image/art%3A10.1007%2Fs10147-022-02166-0/MediaObjects/10147_2022_2166_Fig5_HTML.png)
New treatment paradigm with systemic therapy in intermediate-stage hepatocellular carcinoma | International Journal of Clinical Oncology
Dr Joseph McCollom DO on X: "Combos, combos combos! Dr Lipika Goyal from @MGHCancerCenter discusses combining TKIs and #IO with COSMIC-312, LEAP-002 and early phase Lenva + Pembro 1st line for #HCC #
![Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma - Gray - 2023 - Liver Cancer International - Wiley Online Library Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma - Gray - 2023 - Liver Cancer International - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/dadf0f55-b4d5-495f-93f3-89cfc97a30e4/lci262-fig-0001-m.jpg)
Prognostic and predictive factors for locoregional and systemic therapies in hepatocellular carcinoma - Gray - 2023 - Liver Cancer International - Wiley Online Library
![ESMO - Eur. Oncology on X: "#ESMOasiaweek21: New data for management of #hepatocellularcarcinoma. The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration ➡️ ESMO - Eur. Oncology on X: "#ESMOasiaweek21: New data for management of #hepatocellularcarcinoma. The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration ➡️](https://pbs.twimg.com/media/FEokeU_XsAYjIIU.jpg:large)
ESMO - Eur. Oncology on X: "#ESMOasiaweek21: New data for management of #hepatocellularcarcinoma. The COSMIC-312 trial met its primary endpoint of progression-free survival, but interim overall survival results need further exploration ➡️
![Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Future Oncology Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2020-0283/asset/images/medium/figure2.gif)
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Future Oncology
![Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Future Oncology Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon-2020-0283/asset/images/medium/figure1.gif)
Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design | Future Oncology
![Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology](https://www.thelancet.com/cms/attachment/9b8e0fde-0b92-42c4-bd36-49dbb5824222/gr3_lrg.jpg)
Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial - The Lancet Oncology
HCC CONNECT on X: "#ESMOasiaweek21: this is the place to be for clinical practice changing in advanced #hepatocellularcarcinoma! After ESMO Asia 2019 with #IMbrave150, we are waiting for the presentation of COSMIC-312
![COSMIC-312 Cabozantinib Plus Atezolizumab Improves Progression-Free Survival in Advanced Hepatocellular Carcinoma - The ASCO Post COSMIC-312 Cabozantinib Plus Atezolizumab Improves Progression-Free Survival in Advanced Hepatocellular Carcinoma - The ASCO Post](https://ascopost.com/media/14018827/18-kelley.jpg)
COSMIC-312 Cabozantinib Plus Atezolizumab Improves Progression-Free Survival in Advanced Hepatocellular Carcinoma - The ASCO Post
![COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram](https://www.researchgate.net/publication/351523048/figure/fig1/AS:1028856655925253@1622309950697/Antitumor-and-immunomodulatory-activity-of-cabozantinib-14-16-17-28-31-35-38-40-41-The_Q320.jpg)
COSMIC-312 Study Design. Reproduced with permission from Kelley et al [91]. | Download Scientific Diagram
![Current Oncology | Free Full-Text | Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis Current Oncology | Free Full-Text | Immune-Based Combinations versus Sorafenib as First-Line Treatment for Advanced Hepatocellular Carcinoma: A Meta-Analysis](https://www.mdpi.com/curroncol/curroncol-30-00057/article_deploy/html/images/curroncol-30-00057-g004.png)